Toronto - Free Realtime Quote CAD

Avicanna Inc. (AVCN.TO)

0.2800

0.0000

(0.00%)

As of June 6 at 3:49:55 PM EDT. Market Open.

Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain

Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health NetworkTORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce it has entered into a Sponsored Research Agreement to sponsor a

GlobeNewswire 20 days ago

AVCNF
Avicanna Reports Q1 2025 Results and First Profitable Quarter

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company’s milestone of achieving its first profitable quarter. Management Commentary: "Starting 2025 with positive momentum, we are proud to report our first profitable

GlobeNewswire 25 days ago

AVCNF
Avicanna Announces Revocation of Management Cease Trade Order

TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the Management Cease Trade Order (“MCTO”) issued on April 4, 2025 by the Ontario Securities Commission (“OSC”) has now been revoked. As previously announced, all required filings have been filed by the Company. Follo

GlobeNewswire last month

AVCNF
Avicanna Reports Full Year 2024 Audited Financial Statement

2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its full year 2024 results, audited financial statements with management’s

GlobeNewswire last month

AVCNF
Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update

Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 1 week TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, that further to its March 31, 2025 new release, its application for a management cease trade order (“MCTO”) under National Polic

GlobeNewswire 2 months ago

AVCNF
Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine

Bridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid MedicineLive and Virtual Symposium on June 6th, 2025, at the MaRS Discovery District, Toronto TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it will host its 5th medical s

GlobeNewswire 2 months ago

AVCNF
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order

Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 2 weeks TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announces that it will miss the deadline of March 31, 2025 (“Filing Deadline”) to file the Company’s audited consolidated finan

GlobeNewswire 2 months ago

AVCNF
Avicanna To Hold Full Year 2024 Earnings Conference Call

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a conference call with Aras Azadian, Chief Executive Officer, and also Phil Cardella, Chief Financial Officer, where Mr. Azadian and Mr. Cardella will discuss the Company’s Full Year 2024 financ

GlobeNewswire 2 months ago

AVCNF
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire 2 months ago

PDSB

TELIF

BPTSY
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire 2 months ago

NGENF

BPTSY

HMTXF
Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma

Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in CanadaTORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that Avicanna has entered into a scientific and medical affairs collaboration agreement with Vectura

GlobeNewswire 4 months ago

AVCNF
Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company

Cosmetic registration and delivery into Germany completed in preparation for the initial commercial LaunchTORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the initial delivery of its proprietary topical products into Europe as a part of the previously announce

GlobeNewswire 6 months ago

AVCNF
Avicanna Third Quarter 2024 Earnings: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna ( TSE:AVCN ) Third Quarter 2024 Results Key Financial Results Revenue: CA$6.27m (flat on 3Q 2023). Net loss...

Simply Wall St. 6 months ago

AVCNF
Avicanna Reports Q3 2024

9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce results Q3 2024. “We are pleased to report the results of another quarter showing progr

GlobeNewswire 6 months ago

AVCNF
Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is

GlobeNewswire 6 months ago

AVCNF
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca

1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCICTORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce a large-scale medical cannabi

GlobeNewswire 8 months ago

AVCNF
Avicanna Announces Repayment of Debentures

TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce it has cleared and fully repaid $1,445,000 that was owed under the Debentures of August 2 2023. About Avicanna Inc. Avicanna is a commercial-stage international biopharmaceutical com

GlobeNewswire 9 months ago

AVCNF
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology

USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topicalcannabinoid composition and methods for treating musculoskeletal inflammation and pain TORONTO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the United States Patent and Trade

GlobeNewswire 9 months ago

AVCNF
Avicanna Second Quarter 2024 Earnings: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna ( TSE:AVCN ) Second Quarter 2024 Results Key Financial Results Revenue: CA$6.12m (up 85% from 2Q 2023). Net...

Simply Wall St. 9 months ago

AVCNF
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark

19th international market for Aureus branded products and 22nd market for all Avicanna productsTORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority-owned subsidiary Santa Marta Golden Hemp SAS, the Company has completed the commercial export of

GlobeNewswire 9 months ago

AVCNF

Performance Overview

Return	AVCN.TO	S&P/TSX Composite index (^GSPTSE)
YTD	-6.67%	+7.05%
1-Year	+19.15%	+19.76%
3-Year	+7.69%	+28.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avicanna Inc. (AVCN.TO)

Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain

Avicanna Reports Q1 2025 Results and First Profitable Quarter

Avicanna Announces Revocation of Management Cease Trade Order

Avicanna Reports Full Year 2024 Audited Financial Statement

Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update

Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine

Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order

Avicanna To Hold Full Year 2024 Earnings Conference Call

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma

Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company

Avicanna Third Quarter 2024 Earnings: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna Reports Q3 2024

Avicanna Announces Closing of Non-Brokered Private Placement

Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca

Avicanna Announces Repayment of Debentures

Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology

Avicanna Second Quarter 2024 Earnings: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark

Performance Overview